Trial Profile
Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active Myeloma (TACTAM)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Zedenoleucel (Primary)
- Indications Multiple myeloma; Smoldering multiple myeloma
- Focus Adverse reactions
- Acronyms TACTAM
- 19 Feb 2023 Planned primary completion date changed from 22 Dec 2022 to 22 Dec 2024.
- 28 Oct 2021 Planned End Date changed from 1 Feb 2025 to 22 Dec 2027.
- 28 Oct 2021 Planned primary completion date changed from 1 Jun 2021 to 22 Dec 2022.